Amneal Pharmaceuticals Stock News

Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results - Earnings Call Transcript

Amneal Pharmaceuticals press release (AMRX): Q4 Non-GAAP EPS of $0.18 misses by $0.02.Revenue of $537M (+5.3% Y/Y) beats by $3.59M. Provides 2022 Financial Guidance of $2.15 to…

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2021. “2021 was a transformational year for Amneal as we delivered strong financial results, including 18 percent adjusted EBITDA growth, and advanced our evolution into a diversified biopharmaceutical company. We continued to deepen our robust R&D pipeline and added compelling assets in key growth areas

Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • SIGNA Sports United (NYSE: SSU ) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. • IsoPlexis (NASDAQ: ISO ) is likely to report quarterly loss at $0.68 per share on revenue of $5.45 million. • Innoviz Technologies (NASDAQ: INVZ ) is likely to report quarterly loss at $0.18 per share on revenue of $2.93 million. • International Seaways (NYSE: INSW ) is expected to report quarterly loss at $0.36 per share on revenue of $102.60 million. • Dine Brands Global (NYSE: DIN ) is estimated to report quarterly earnings at $1.27 per share on revenue of $236.67 million. • Dollar Tree (NASDAQ: DLTR ) is expected to report quarterly earnings at $1.77 per share on revenue of $7.12 billion. • Valens Semiconductor (NYSE: VLN ) is projected to report quarterly loss at $0.06 per share on revenue of $20.04 million. • Sterling Check (NASDAQ: STER ) is projected to report quarterly earnings at $0.17 per share on revenue of $152.50 million.

Amneal Pharmaceuticals (AMRX) said the U.S. FDA approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.The product will be marketed…

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q4 earnings results on Wednesday, Mar. 2, before market open.Consensus EPS estimate is $0.20 (+42.9% Y/Y)

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The U.S. Food and Drug Administration ((FDA)) approved four generic injectables products from Amneal Pharmaceuticals (AMRX).Dexamethasone sodium phosphate injection, USP 10…

Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $83.5 million in cash.  The acqui

Amneal Pharmaceuticals, Inc. (NYSE:AMRX)s share price gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $4.27, but opened at $4.51. Amneal Pharmaceuticals shares last traded at $4.42, with a volume of 11,312 shares traded. Specifically, CEO Chirag K. Patel acquired 100,000 shares of the companys stock in []

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) CEO Chirag K. Patel bought 100,000 shares of the companys stock in a transaction that occurred on Wednesday, December 15th. The shares were bought at an average price of $4.13 per share, for a total transaction of $413,000.00. The transaction was disclosed in a legal filing with the SEC, which can []